News | August 17, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
Reinforcing commitment to ethical and sustainable growth
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
The new Zigly center features and offers comprehensive veterinary services
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
Subscribe To Our Newsletter & Stay Updated
